PROMIS NEUROSCIENCES ISSUES CHAIRMAN’S UPDATE MEMORANDUM AND WHITE PAPER ON ALZHEIMER’S DISEASE

TORONTO, Ontario and CAMBRIDGE, MA. — October 24, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has issued a memorandum, compiled by its Executive Chairman of the Board, that provides context for the company’s recent program progress as well as a white paper analysis of Biogen’s October 22, 2019 decision to submit its amyloid-beta (Aβ)-targeting drug candidate, aducanumab  for Alzheimer’s disease (AD) to the U.S. Food and Drug administration (FDA) in early 2020. The new resources detail how each development demonstrates strong momentum across the company’s preclinical programs. MORE>>